Pre-diagnostic Clonal Hematopoiesis Raises Risk of Second Cancers in Patients With Primary Cancer

Overview

Clonal hematopoiesis of indeterminate potential, commonly abbreviated as CHIP, refers to a condition in which a small population of blood-forming stem cells acquires genetic changes and begins to expand in the bone marrow, even though the person does not yet have a blood cancer. CHIP becomes more common with age and has been linked to an increased risk of later hematologic malignancies, such as myelodysplastic neoplasms and leukemia, as well as some solid tumors.

In this study, researchers asked a clinically important question: among people who already have a first primary cancer, does CHIP detected before the cancer diagnosis predict a higher risk of developing a second cancer later on? The answer was yes. Patients with pre-diagnostic CHIP had a significantly higher risk of second cancers than those without CHIP.

What the study examined

The investigation was a prospective cohort study using data from the UK Biobank, a large long-term population health resource. The researchers included 63,690 participants who received a first diagnosis of primary cancer between 2006 and 2022. They then compared outcomes in people with and without CHIP detected before the cancer diagnosis.

Among these patients, 2,860 had pre-diagnostic CHIP and 60,626 did not. The team used Cox regression analysis, a standard statistical method for time-to-event data, to estimate the relationship between pre-diagnostic CHIP and the future development of second cancers.

The median follow-up period was 3.9 years, which means half the participants were followed longer than that and half for a shorter time. During follow-up, researchers assessed whether patients developed a new, separate cancer after the first primary cancer.

Key findings

Patients with primary cancer who had pre-diagnostic CHIP faced a higher overall risk of any second cancer than those without CHIP. The hazard ratio was 1.3, with a 95% confidence interval of 1.2 to 1.5. In practical terms, this suggests about a 30% higher relative risk, although the actual absolute risk depends on the type of first cancer, treatment received, age, and other health factors.

The increased risk was especially noticeable in patients whose first cancers were:

• Myelodysplastic neoplasms
• Myeloproliferative neoplasms
• Non-Hodgkin lymphoma
• Breast cancer

When the researchers looked at the type of second cancer, the strongest excess risk was seen for:

• Second myeloid malignancies
• Second non-myeloid hematologic malignancies

The risk was also particularly associated with certain CHIP driver mutations, including DNMT3A, TET2, SRSF2, and JAK2. These genes are well known in blood cancer biology because they regulate DNA methylation, RNA splicing, and signaling pathways that control blood cell growth and differentiation.

Why CHIP may matter after a first cancer

CHIP is important because it may represent a pre-existing biological vulnerability in the blood system. Several mechanisms could explain the higher second-cancer risk observed in this study:

• Shared predisposition: CHIP may reflect age-related genomic instability and a general tendency toward malignant transformation.
• Treatment sensitivity: Cancer therapies such as chemotherapy and radiotherapy can further stress blood-forming cells, potentially accelerating expansion of mutated clones.
• Inflammation and immune effects: CHIP has been linked to chronic inflammation, which may contribute to cancer development and progression.
• Clonal evolution: Over time, CHIP clones may acquire additional mutations and evolve into overt hematologic malignancies.

Although this study cannot prove cause and effect, the findings are consistent with the idea that CHIP is not merely a benign age-related finding. In some patients, it may mark a group at higher risk for future malignancy.

Clinical implications

These results have several potential implications for cancer care and survivorship. First, clinicians may need to pay closer attention to patients with known CHIP when planning follow-up after a primary cancer diagnosis. Second, the findings support the idea that blood-based genomic markers could one day help personalize cancer surveillance.

That said, CHIP testing is not yet a routine standard for all cancer patients, and the presence of CHIP does not mean a person will definitely develop a second cancer. Many individuals with CHIP never develop blood cancer at all. Therefore, results should be interpreted as a risk marker, not a diagnosis.

For patients with primary cancer and pre-diagnostic CHIP, practical management may include:

• Careful long-term follow-up
• Monitoring blood counts over time
• Attention to new symptoms such as unexplained fatigue, infections, bruising, or weight loss
• Coordination between oncology and hematology teams when appropriate

In the future, risk-adapted surveillance strategies may be developed for individuals with CHIP, especially those carrying high-risk mutations or those who have already received genotoxic cancer therapy.

Study strengths and limitations

This study has several strengths. It was large, prospective, and based on real-world data from a well-characterized cohort. The use of longitudinal follow-up strengthens the ability to observe future cancer outcomes after CHIP detection.

However, there are also limitations to consider:

• CHIP was not necessarily measured in all participants using the same assay or at the same time point.
• The follow-up period, while meaningful, was still relatively short for some cancer outcomes.
• Residual confounding may remain, since cancer risk is influenced by age, smoking, treatment type, genetics, and other comorbidities.
• The study shows association, not proof that CHIP causes second cancers.

Even with these limitations, the results are clinically relevant and help build a more complete picture of how age-related blood mutations may influence cancer risk after a first malignancy.

Bottom line

Among patients with a first primary cancer, pre-diagnostic CHIP was associated with a higher risk of developing a second cancer, especially second blood cancers. The association was strongest for CHIP driven by DNMT3A, TET2, SRSF2, and JAK2 mutations. These findings suggest that CHIP may serve as a useful biomarker for identifying cancer survivors who could benefit from closer long-term monitoring.

As research continues, CHIP may become an important part of precision oncology and survivorship care, helping clinicians better estimate risk and tailor follow-up for patients with cancer.